The postmarketing safety problems seen with Endo Pharmaceuticals Inc.'s withdrawn long-acting opioid Opana ER have led to a new level of US FDA preapproval scrutiny of opioid formulations purported to be abuse deterrent.
The agency is increasingly weighing the downstream public health impacts when opioid formulations that are designed to deter abuse are...